Invention Grant
- Patent Title: VEGF/DLL4 binding agents and uses thereof
-
Application No.: US15847335Application Date: 2017-12-19
-
Publication No.: US10730940B2Publication Date: 2020-08-04
- Inventor: Austin L. Gurney , Aaron Ken Sato , Christopher John Bond
- Applicant: OncoMed Pharmaceuticals, Inc.
- Applicant Address: US CA Redwood City
- Assignee: OncoMed Pharmaceuticals, Inc.
- Current Assignee: OncoMed Pharmaceuticals, Inc.
- Current Assignee Address: US CA Redwood City
- Agency: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- Main IPC: A61K39/395
- IPC: A61K39/395 ; C07K16/22 ; C07K16/28 ; C07K16/46 ; A61K45/06 ; A61K31/4745 ; A61K31/7068 ; A61K39/00 ; A61K45/00 ; C07K16/18 ; C07K16/30
Abstract:
The present invention relates to VEGF-binding agents, DLL4-binding agents, VEGF/DLL4 bispecific binding agents, and methods of using the agents for treating diseases such as cancer. The present invention provides antibodies that specifically bind human VEGF, antibodies that specifically bind human DLL4, and bispecific antibodies that specifically bind human VEGF and/or human DLL4. The present invention further provides methods of using the agents to inhibit tumor growth. Also described are methods of treating cancer comprising administering a therapeutically effect amount of an agent or antibody of the present invention to a patient having a tumor or cancer.
Public/Granted literature
- US20180305449A1 VEGF/DLL4 Binding Agents and Uses Thereof Public/Granted day:2018-10-25
Information query
